Vectus Biosystems Ltd. operates as a drug discovery and development company. It researches a treatment for fibrosis and high blood pressure, which includes the therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. Its lead compounds include VB0004, VB4-A32, VB4-A79, and VB4-P5. The company was founded by Karen Duggan on December 12, 2005 and is headquartered in Rosebery, Australia.